Argifin, an esteemed biomedical innovation, is a pharmacotherapeutic marvel meticulously designed for the efficacious amelioration of various intricate cardiovascular ailments. Within its composition lies the veritable elixir of arginine, an innate amino acid proficient in stimulating the augmentation of nitric oxide concentrations within the corporeal establishment. Consequently, this preeminent phenomenon impeccably fosters vasodilation, culminating in optimized hemodynamic dynamics, and the abatement of perilously elevated arterial tension.
CAT No: R2081
CAS No: 243975-37-3
Synonyms/Alias: Argifin;243975-37-3;CHEMBL197199;(2R,5S,8S,11S,15S)-5-[3-[[amino-(methylcarbamoylamino)methylidene]amino]propyl]-8-benzyl-2,7-dimethyl-3,6,9,13,17-pentaoxo-1,4,7,10,14-pentazacycloheptadecane-11,15-dicarboxylic acid;DTXSID00332297;(2R,5S,8S,11S,15S)-5-(3-((amino-(methylcarbamoylamino)methylidene)amino)propyl)-8-benzyl-2,7-dimethyl-3,6,9,13,17-pentaoxo-1,4,7,10,14-pentazacycloheptadecane-11,15-dicarboxylic acid;1w9v;1wb0;BDBM10853;DTXCID40283390;FTD 0668;HY-P2274;BDBM50173286;DB03632;CS-0121055;NS00071704;(2R,5S,8S,11S,15S)-8-benzyl-2,7-dimethyl-5-[3-({[(methylcarbamoyl)amino]methanimidoyl}amino)propyl]-3,6,9,13,17-pentaoxo-1,4,7,10,14-pentaazacycloheptadecane-11,15-dicarboxylic acid;5-[3-[amino-(methylcarbamoylamino)methylidene]aminopropyl]-8-benzyl-2,7-dimethyl-3,6,9,13,17-pentaoxo-1,4,7,10,14-pentazacycloheptadecane-11,15-dicarboxylic acid;Cyclo[D-alanyl-N5-[imino[[(methylamino)carbonyl]amino]methyl]-L-ornithyl-N-methyl-L-phenylalanyl-L-beta-aspartyl-L-beta-aspartyl] (9CI);
Chemical Name: (2R,5S,8S,11S,15S)-5-[3-[[amino-(methylcarbamoylamino)methylidene]amino]propyl]-8-benzyl-2,7-dimethyl-3,6,9,13,17-pentaoxo-1,4,7,10,14-pentazacycloheptadecane-11,15-dicarboxylic acid
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C29H41N9O10 |
M.W/Mr. | 675.7 |
Sequence | Three Letter Code:D-N(1)Ala-Arg(CONHMe)(CONHMe)-N(Me)Phe-Asp(2)-OH.N(2)Asp(1)-OH |
InChI | InChI=1S/C29H41N9O10/c1-15-23(41)35-17(10-7-11-32-28(30)37-29(48)31-2)25(43)38(3)20(12-16-8-5-4-6-9-16)24(42)36-19(27(46)47)14-22(40)34-18(26(44)45)13-21(39)33-15/h4-6,8-9,15,17-20H,7,10-14H2,1-3H3,(H,33,39)(H,34,40)(H,35,41)(H,36,42)(H,44,45)(H,46,47)(H4,30,31,32,37,48)/t15-,17+,18+,19+,20+/m1/s1 |
InChI Key | UHBHXSDKGLPPGO-HTDHLNIYSA-N |
Canonical SMILES | CC1C(=O)NC(C(=O)N(C(C(=O)NC(CC(=O)NC(CC(=O)N1)C(=O)O)C(=O)O)CC2=CC=CC=C2)C)CCCN=C(N)NC(=O)NC |
Isomeric SMILES | C[C@@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](CC(=O)N[C@@H](CC(=O)N1)C(=O)O)C(=O)O)CC2=CC=CC=C2)C)CCCN=C(N)NC(=O)NC |
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.